- The FDA Advisory Committee has recommended approving flibanserin, a Sprout Pharmaceuticals drug meant to treat women with hypoactive sexual desire disorder (HSDD). The media has often referred to flibanserin as a female Viagra.
- Palatin (NYSE:PTN), which is currently taking enrollments for Phase 3 trials of its bremelanotide HSDD drug, has jumped to $1.16 in AH trading.
Palatin +28.9%; FDA AdComm recommends approving HSDD drug
Recommended For You
About PTN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PTN | - | - |
Palatin Technologies, Inc. |